Investors

Investor Relations

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of new inhalation products for the treatment of chronic respiratory diseases and lung conditions. In early testing, the Thin Film Freezing (TFF) proprietary platform significantly improved the solubility of drugs that have poor water solubility.

In June 2021, TFF Pharmaceuticals held a conversation with Key Opinion Leaders to discuss its TFF Tacrolimus program for lung transplant as well as applications of its Thin Film Freezing technology for vaccine applications. View the presentation here.

Learn more about TFF’s Thin Film Freezing technology, its lead programs, TFF Voriconazole and TFF Tacrolimus, and its broad-reaching partnering strategy in the corporate overview video below.

August 12, 2021: TFF Pharmaceuticals Second Quarter 2021 Financial and Business Results Conference

 

TFF Pharmaceuticals Corporate Overview – March 2020


Volume:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation of COVID-19 Antibody, AUG-3387, Neutralizes SARS-CoV-2 Infection and Reduces Viral Load
October 14, 2021
Results published in bioRxiv Show That Delivery of Dry Powder AUG-3387 Following Viral Inoculation Led to Dose-Dependent Reduction in Lung Viral Load in Hamsters Dry Powder Formulations Show Equivalent Binding as Original Antibody with No Loss of Biologic Activity Study Indicates AUG-3387 Binds to
Read More

Featured Presentation


About

Management Board of Directors Fact Sheet

Science

The Problem The Solution Benefits

Products

Regulatory Pathway Initial Focus

More

Investors Contact

© 2021 TFF Pharmaceuticals, Inc.

All Rights Reserved.

Privacy Policy.
Top